BioConsortia raises additional $15M in series B funding

BioConsortia, Inc., an agricultural biotechnology company that uses a proprietary method for the selection of beneficial microbial consortia for crop improvement, has raised an additional $15 million in Series B funding. Khosla Ventures and Otter Capital participated equally in the round. This fund-raising round, along with the recent appointment of Marcus Meadows-Smith as the CEO of BioConsortia, accelerates the company’s plans to market the use of microbial consortia as seed treatments and soil additives.

BioConsortia has developed a proprietary system that uses accelerated microbial selection and the latest genomic techniques to define products for specific crop improvement traits based on an optimum community of microbes, or consortia, that work together to increase crop yields with no genetic modification required. The system rapidly identifies the right consortia and can apply to both conventional and transgenic crops.

In addition to product development and marketing, BioConsortia will use the funds to invest in the necessary resources to build collaborative partnerships with seed, fertilizer and crop production companies.

For more information:
Bioconsortia
Email: info@bioconsortia.com
www.bioconsortia.com